FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated by the Sponsor.

Conditions

Non Small Cell Lung Cancer
Colorectal Cancer
Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Head and Neck Cancer
GastroEsophageal Cancer

Interventions

DRUG: FT536
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: IL-2
COMBINATION_PRODUCT: Avelumab
COMBINATION_PRODUCT: Pembrolizumab
COMBINATION_PRODUCT: Nivolumab
COMBINATION_PRODUCT: Atezolizumab
COMBINATION_PRODUCT: Trastuzumab
COMBINATION_PRODUCT: Cetuximab
COMBINATION_PRODUCT: Amivantamab
DRUG: IL-2

Sponsor

Fate Therapeutics